Info

84. Dreger P: Prognostic factor for survival after autologous stem cell transplantation for chronic lymphocytic leukemia (CLL): The EBMT experience. 2000.

85. Dreger P: Efficacy and prognostic implications of early autologous stem cell transplantation for poor-risk chronic lymphocytic leukemia (CLL). Blood 96:483a, 2000.

86. El Rouby S: p53 gene mutation in B-cell chronic lym-phocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82:3452-3459, 1993.

87. Hamblin TJ: Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848-1854, 1999.

88. Hamblin TJ: Immunoglobulin V genes associated with a more aggressive form of chronic lymphocytic leukemia. Blood 95:2455-2457, 2000.

89. Hamblin TJ: CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99:1023-1029, 2002.

90. Horowitz M: Hematopoietic stem cell transplantation (SCT) for chronic lymphocytic leukemia (CLL). Blood 96:522a, 2000.

91. Jabbour E: Stem cell transplantation for chronic lym-phocytic leukemia: should not more patients get a transplant? Bone Marrow Transplant 34:289-297, 2004.

92. Khouri IF: Hematopoietic stem cell transplantation for chronic lymphocytic leukemia. Curr Opin Hematol 5:454-459, 1998.

93. Khouri IF: Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy 4:217-221, 2002.

94. Khouri IF: Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 32:28-35, 2004.

95. Lin TS: Augologous stem cell transplantation for non-Hodgkin's lymphoma. Curr Hematol Rep 2:310-315, 2003.

96. Michallet MR: Allogeneic hematopoietic stem cell transplantation (HSCT) for chronic lymphocytic leukemia (CLL): results and prognostic factors for survival after transplantation: analysis from EBMT registry. Blood 96:205a, 2000.

97. Milligan DW: Autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses: results of the MRC Pilot Study. Blood. In press.

98. Montserrat E: Autologus stem cell transplantation (ASCT) for chronic lymphocytic leukemia (CLL): results in 107 patients. Blood 94:396a, 1999.

99. Rabinowe SN: Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 82:1366-1376, 1993.

100. Rassenti LZ: ZAP-70 is a more reliable marker of disease progression risk than immunoglobulin mutation status in chronic lymphocytic leukemia. Blood 102:34a, 2003.

101. Ritgen M: Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 101:2049-2053, 2003.

102. Ritgen M: Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood. In press.

103. Schetelig: Reduced non-relapse mortality after reduced intensity conditioning in advance chronic lymphocytic leukemia. Ann Hematol 81(Suppl 2):S47-48, 2002.

104. Schetelig J: Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 21: 2747-2753, 2003.

105. Petersdof EW: Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood 104:9. 2004.

This page intentionally left blank

0 0

Post a comment